Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early guidance for Sars-Cov-2 health policies in India: Social Distancing amidst Vaccination and Virus Variants*

Yi Zhang, Sanjiv Kapoor
doi: https://doi.org/10.1101/2022.02.02.22270353
Yi Zhang
1Computational Decision Science Laboratory, Illinois Institute of Technology, Chicago, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjiv Kapoor
1Computational Decision Science Laboratory, Illinois Institute of Technology, Chicago, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kapoor@iit.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Policy decisions during the SARS-COV-2 pandemic were complicated due to virus variants and the impacts of societal restrictions. Accurate predictive models were required in this context. In this paper we report results from a model that helped in predicting the impact of SARS-CoV-2 virus transmission in India over a period of a number of months from June, 2021 to March 2022. These models were applied in the context of enabling policy decisions to tackle the impact of the pandemic in India culminating in early warning projections for the Omicron variant and used for advise on preemptive policy actions.

Methods Our model utilizes a deterministic compartment models incorporating a dynamic transmission factor, dependent on the population’s behavior as a function of the reported confirmed cases of virus transmission as well as methods for estimation of the increase in susceptible population when social distancing mandates are relaxed. The model used to predict viral growth incorporates the state of vaccination and the virus variants that form part of the transmission dynamics as well the lockdown state of the population. NPI actions were used in India to contain the spread of infections during the period of study, especially during the surge of the Omicron variant of the virus. Further we present the impact of lockdown policies and illustrate the advantage of adopting partial lockdown policies in the early period of 2022. Based on the models, our predictive analysis, when applied to the Omicron variant, illustrated substantial improvement even when partial lockdown is planned.

Findings This report presents models and results that incorporated the impact of vaccination rates and the Omicron variant and were used to establish projections on the growth of Sars-Cov2 infections in India for the period from July 2021 till March 2022. The growth rate of the Omicron virus was deduced from data that originated from South Africa in November 2021. These projections were submitted to a pivotal government organization involved in developing a national public health strategy to address the pandemic and, as per personal communication, were considered when formulating national policy. The pandemic had a subdued impact in India during the period from July 2021 till date as evident from the deaths reported by the government. The projections were made every month and cases were projected over the next 4-16 weeks. The projections of cumulative cases during the Omicron wave had low errors when measured using RMSE per capita and had a MAPE error of 17.8% when measured 15 days after start of the projection on December 5th, 2021.

Discussion The composed model was found to be useful in providing predictive and data based analytic input to inform early warning approaches in the context of policy based interventions to control the pandemic in India. The model provided monthly early prediction of the spread and impact of the SARS-COV-2 virus in India, state-wise, during the phase of removal of government lockdown in the second half of 2021. The early warning system incorporated the impact of the Omicron variant to provide predictions for Indian states and the country.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded in part by National Science Foundation, USA (Grant No. 2028274)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Openly available data from MOHW, India available at: https://github.com/datameet/covid19/blob/master/data/mohfw.json

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • * Research sponsored in part by NSF. grant No. 2028274.

  • This version has additional material in section 3 on the impact of lockdowns and methodology in section 4.

Data Availability

Data is available on repositories

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 06, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early guidance for Sars-Cov-2 health policies in India: Social Distancing amidst Vaccination and Virus Variants*
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early guidance for Sars-Cov-2 health policies in India: Social Distancing amidst Vaccination and Virus Variants*
Yi Zhang, Sanjiv Kapoor
medRxiv 2022.02.02.22270353; doi: https://doi.org/10.1101/2022.02.02.22270353
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Early guidance for Sars-Cov-2 health policies in India: Social Distancing amidst Vaccination and Virus Variants*
Yi Zhang, Sanjiv Kapoor
medRxiv 2022.02.02.22270353; doi: https://doi.org/10.1101/2022.02.02.22270353

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (578)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11095)
  • Forensic Medicine (8)
  • Gastroenterology (621)
  • Genetic and Genomic Medicine (3163)
  • Geriatric Medicine (307)
  • Health Economics (561)
  • Health Informatics (2041)
  • Health Policy (862)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12707)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2980)
  • Nursing (163)
  • Nutrition (462)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1549)
  • Ophthalmology (476)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (910)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2780)
  • Public and Global Health (5588)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (631)
  • Respiratory Medicine (758)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)